ImmunoGen, Inc. (Nasdaq: IMGN) today announced that it has initiated Phase II testing of its IMGN901 product candidate for first-line treatment of SCLC.
“Our experience with IMGN901 to date - preclinical and clinical - supports Phase II evaluation of IMGN901 for first-line use in SCLC”
The Phase II assessment begun today, also known as the NORTH trial, is designed to evaluate whether the addition of IMGN901 to standard first-line care for SCLC meaningfully impacts duration of progression-free survival (PFS). With SCLC, the efficacy of first-line treatment is considered to be particularly important due to the low likelihood of obtaining a marked, sustained response with any subsequent treatment.
"Our experience with IMGN901 to date - preclinical and clinical - supports Phase II evaluation of IMGN901 for first-line use in SCLC," commented James O'Leary, MD, Vice President and Chief Medical Officer. "SCLC almost universally expresses the CD56 antigen targeted by IMGN901, and there is a clear need for more effective treatments for this cancer. We have a number of clinical sites already open for patient enrollment, with many additional sites on track to open over the next month."
Patient-derived organoids: Transforming cancer research and personalized medicine